). In the DCT, the final adjustment of renal sodium excretion is regulated by the thiazide-sensitive Na ϩ -Cl Ϫ cotransporter (NCC), which is activated by the renin-angiotensin-aldosterone system (RAAS). The aim of this study was to gain more insight into the molecular mechanisms of CsA-induced hypomagnesemia and hyponatremia. Therefore, the renal expression of TRPM6, TRPM7, EGF, EGF receptor, claudin-16, claudin-19, and the NCC, and the effect of the RAAS on NCC expression, were analyzed in vivo in a rat model of CsA nephrotoxicity. Also, the effect of EGF administration on these parameters was studied. CsA significantly decreased the renal expression of TRPM6, TRPM7, NCC, and EGF, but not that of claudin-16 and claudin-19. Serum aldosterone was significantly lower in CsA-treated rats. In control rats treated with EGF, an increased renal expression of TRPM6 together with a decreased fractional excretion of Mg 2ϩ (FE Mg 2ϩ ) was demonstrated. EGF did not show this beneficial effect on TRPM6 and FE Mg 2ϩ in CsA-treated rats. These data suggest that CsA treatment affects Mg 2ϩ homeostasis via the downregulation of TRPM6 in the DCT. Furthermore, CsA downregulates the NCC in the DCT, associated with an inactivation of the RAAS, resulting in renal sodium loss.
CYCLOSPORINE (CsA) is a calcineurin inhibitor which inhibits T cell activation by blocking the transcription of cytokine genes (29) . The most serious and dose-limiting side effect of this immunosuppressive drug is nephrotoxicity. Acute nephrotoxicity is characterized by renal vasoconstriction, which is dose related and reversible after dose reduction or discontinuation of CsA. Chronic CsA-induced nephrotoxicity can be progressive and irreversible. The histological changes include tubular atrophy, medial arteriolar hyalinosis, and striped fibrosis with infiltration of mononuclear cells. Tubulointerstitial fibrosis is the most important and determining factor, which leads to irreversible loss of kidney function in chronic kidney diseases (1, 13, 28) . CsA also induces functional alterations and ion homeostasis disturbances like hypomagnesemia and magnesium (Mg 2ϩ ) wasting, hyponatremia, hyperkalemia, hyperchloremic metabolic acidosis, and hyperuricemia (5, 18) .
Hypomagnesemia after treatment with calcineurin inhibitors is due to renal Mg 2ϩ loss (3, 33) . The major site of passive Mg 2ϩ reabsportion is the thick ascending limb (TAL), where 70% of the Mg 2ϩ is reabsorbed paracellularly. The tight junction proteins claudin-16 (also known as paracellin-1) and claudin-19 are key players in this paracellular Mg 2ϩ transport (20, 22) . It was shown by Chang et al. (7) that CsA reduces claudin-16 expression in vitro in TAL cells.
Recently, two other ion channels which play an important role in Mg 2ϩ homeostasis were identified, TRPM6 and TRPM7. They belong to the transient receptor potential subfamily melastatin (TRPM). TRPM6 has an expression pattern predominantly present in absorbing epithelia. In the kidney, TRPM6 is expressed in the distal convoluted tubule (DCT), known as the main site of active transcellular Mg 2ϩ reabsorption along the nephron. TRPM7 is ubiquitously expressed and implicated in cellular Mg 2ϩ homeostasis, cell death, and cell cycle regulation (19, 42) .
Ikari et al. (21) found that CsA decreased TRPM6 expression in vitro in cell culture of rat kidney epithelial cells (NRK-52E). Furthermore, it is known that CsA administration results in a decreased renal expression of epidermal growth factor (EGF) in the rat (9) . Recently, it was shown that EGF stimulates Mg 2ϩ reabsorption in the DCT via its receptor on the basolateral membrane and via activation of TRPM6 in the apical membrane. EGF-mediated stimulation of TRPM6 occurs via signaling through SRC kinases and Rac1 in vitro, thereby redistributing endomembrane TRPM6 to the plasma membrane (16, 41) .
Calcineurin inhibitors also affect sodium (Na ϩ ) reabsorption, since hyponatremia due to renal sodium loss has been described in renal transplant patients treated with tacrolimus or CsA (18, 51) . The epithelial sodium channel and mainly the thiazide-sensitive Na ϩ -Cl Ϫ cotransporter (NCC) in the DCT reabsorb sodium to make the final adjustment of renal sodium excretion (15, 27) . The renin-angiotensin-aldosterone system (RAAS) stimulates NCC activity. On the one hand, ANG II induces rapid trafficking of the NCC from stores in subapical vesicles to the plasma membrane, and on the other hand both ANG II and aldosterone independently phosphorylate and thereby activate the NCC (37, 44) .
The aim of this study was to gain more insight into the molecular mechanisms of CsA-induced hypomagnesemia and hyponatremia. We investigated whether we could confirm the in vitro finding that claudin-16 and TRPM6 are downregulated after CsA administration in an in vivo rat model of CsA nephrotoxicity. The animal model has been validated with regard to histological characteristics, the inflammatory component, and the expression of profibrotic factors transforming growth factor (TGF)-␤ and plasminogen activator inhibitor (PAI)-1. We further hypothesized that EGF administration leads to an increase in TRPM6 expression in the DCT in control rats and to a reduction of TRPM6 downregulation in CsA-treated rats. Furthermore, we investigated the effect of CsA on the expression of the NCC in the DCT. To determine the influence of the RAAS on NCC expression in the rat model, serum aldosterone levels and renal preprorenin mRNA levels were measured.
MATERIALS AND METHODS
To validate the animal model of CsA nephrotoxicity, the following analyses were performed: determination of serum creatinine, visualization of CsA-induced morphological lesions, phenotyping of inflammatory cells, and assessment of renal mRNA levels of the proinflammatory factors TGF-␤ and PAI-1.
The study's aims were addressed by determination of the following parameters: the fractional excretion of Mg 2ϩ (FE Mg 2ϩ ) and Na ϩ (FE Na ϩ ), the expression of TRPM6, TRPM7, claudin-16, and claudin-19, EGF, the EGF receptor (EGFR), the NCC, and preprorenin and serum aldosterone levels. Subsequently, the effect of human (h) EGF administration on these parameters was evaluated.
Ethical approval for animal studies was achieved from the Medical Ethical Committee on Animal Experimentation at the University of Antwerp, Belgium.
Animal model. Forty-eight male Wistar rats (Charles River, Brussels, Belgium), weighing at the start of the experiments between 180 and 200 g, were housed four per cage, at 22 Ϯ 2°C with a 12:12-h light-dark cycle. They had free access to water and were fed with a normal-Mg 2ϩ and low-sodium diet (0.05% sodium, Harlan Laboratories, Horst, The Netherlands), a necessary constituent of the CsA nephrotoxicity rat model: salt depletion accelerates the development of chronic CsA renal injury in the rat (35) .
Experimental set-up. Rats were divided into four groups (each containing n ϭ 12) and treated for 28 days as follows.
Control rats received a daily subcutaneous injection of saline/PBS in a volume equal to the EGF-and/or CsA-treated groups.
ControlϩEGF rats received a daily subcutaneous injection of EGF (150 g·kg Ϫ1 ·day Ϫ1 ) and saline in a volume equal to the CsA-treated groups.
CsA-treated rats received a daily subcutaneous injection of CsA (15 mg·kg Ϫ1 ·day Ϫ1 ) and PBS in a volume equal to the EGF-treated groups.
CsA-treatedϩEGF rats received a daily subcutaneous injection of CsA (15 mg·kg Ϫ1 ·day Ϫ1 ) and EGF (150 g·kg Ϫ1 ·day Ϫ1 ). CsA (SandImmun, Novartis, Vilvoorde, Belgium) was diluted in saline to a final concentration of 7.35 mg/ml to obtain a dose of 15 mg·kg Ϫ1 ·day Ϫ1 . The time interval of CsA treatment was chosen so that there would be neither interstitial fibrosis nor tubular atrophy at the time of death. Lyophilized hEGF (PeproTech, London, UK) was diluted in PBS to a final concentration of 87.6 g EGF/ml to obtain a dose of 150 g·kg Ϫ1 ·day Ϫ1 . Because rat EGF was not commercially available, hEGF was used for this experiment. Literature shows sufficient evidence that hEGF works in rats in the concentration used in this experiment (4, 17, 45) .
Sample collection. One week before the first administration, the rats were caged individually in a metabolic cage to obtain a 24-h urine collection. Also, 0.9 ml of blood was collected from the tail vein.
After 28 days of treatment, according to the study design, the rats were caged individually to obtain a second 24-h urine collection. Meanwhile, the rats were housed four per cage. Afterward, they were euthanized by an overdose of pentobarbital sodium (100 -150 mg/kg) intraperitoneally. Blood samples were taken from the vena cava inferior at the time of death. The kidneys were quickly prelevated and decapsulated. The right kidney was snap-frozen in liquid nitrogen and stored at Ϫ80°C until RNA extraction was performed. The left kidney was cut into 2-mm-thick transverse slices and processed for further histological analysis using different fixation procedures (described below).
Serum Serum and urine and K ϩ levels were measured using an indirect potentiometric method with a dimension Vista 1500 System (Siemens Healthcare Diagnostics, Deerfield, IL).
FE Na ϩ was calculated as FENa ϭ 100 ϫ (UNa ϫ PCr)/(PNa ϫ U Cr), where UNa is urinary excretion of Na ϩ (mmol/l), PCr is plasma creatinine (mg/dl), P Na is plasma Na ϩ (mmol/l), and UCr is urinary excretion of creatinine (mg/dl).
FE K ϩ was calculated as FEK ϭ 100 ϫ (UK ϫ PCr)/(PK ϫ UCr), where U K is urinary excretion of K ϩ (mmol/l), PCr is plasma creatinine (mg/dl), PK is plasma K ϩ (mmol/l), and UCr is urinary excretion of creatinine (mg/dl).
CsA levels were determined in whole blood using the CsA FLEX reagent cartridge (Siemens Healthcare Diagnostics).
Serum aldosterone levels. Serum aldosterone levels were measured using a rat aldosterone ELISA Kit (Hölzel Diagnostika Handels, Cologne, Germany). Samples were diluted in a sample diluent supplied with the kit (1:100). The detection range was 31.2-2,000 pg/ml.
CsA-induced morphological lesions. For light microscopy, the rat kidney slices were fixed in formol for 24 h, embedded in paraffin, sectioned at 5 m, and stained with periodic acid-Schiff reagent or Sirius red collagen stain. The tissue samples were evaluated for tubular injuries and juxtaglomerular apparatus (JGA) hyperplasia by three observers blinded to the treatment groups. The percentage of dilated or vacuolized tubules was counted in at least 28 cortical fields (ϫ250 magnification). The following score was used: 0, no tubular injury; 1, Ͻ10% of tubules injured; 2, 10 -25% of tubules injured; 3, 25-50% of tubules injured; 4, 50 -75% of tubules injured; and 5, Ͼ75% of tubules injured (28) . JGA hyperplasia was counted in all glomeruli and expressed as the percentage of total number of glomeruli. Sirius red-stained sections were scanned with an Olympus BX61 Motorized Research Microscope (Olympus, Tokyo, Japan) equipped with analysis pro 5.0 software (Olympus). Because there was no visible fibrosis, the amount of collagen was measured. After processing of the image, the total amount of collagen was measured and expressed as the percentage of the total cortex.
Phenotyping of inflammatory cells. The formol-fixed, paraffinembedded renal tissue was stained with the ED1 monoclonal antibody (Acris Antibodies, Hiddenhausen, Germany) directed to an antigen of tissue macrophages and peripheral blood granulocytes. Infiltration was quantified by counting immunoreactive cells in 28 randomly chosen areas (magnification ϫ200) in the cortex (11) . Thirty glomeruli per renal section were examined for infiltrating cells. Inflammatory cells contained within large blood vessels or surrounded by erythrocytes were excluded from all counts. The results were expressed as absolute numbers of immunoreactive cells per square millimeter or per glomerular cross section. Sections were evaluated blinded for the subgroup division of the rats. mRNA isolation. Total RNA was extracted from the kidneys using a column-based technique (RNeasy Minikit, Qiagen, KJ Venlo, The Netherlands). Purified total RNAs were treated with DNase to obtain DNA-free RNA (Turbo DNase free, Ambion, Applied Biosystems, Lennik, Belgium). cDNA was synthesized using a Transcriptor First Strand cDNA Synthesis Kit (AMV, Roche Applied Science, Indianapolis, IN).
Real-time RT-PCR. To examine the mRNA expression of TRPM6, the NCC, EGFR, EGF, and renin, quantitative real-time RT-PCR was performed using LightCycler Taqman Master (Roche, Vilvoorde, Belgium). The PCR reaction was performed in a 20-l reaction volume containing 5 l of cDNA sample, 4 l of MasterMix, and a forward primer, reverse primer, and probe. TGF-␤, PAI-1, TRPM7, claudin-16, and claudin-19 mRNA expression was examined using LightCycler FastStart DNA Master plus SYBR green I (Roche). Preincubation was performed at 95°C for 10 min before PCR cycling (50 cycles) at 95°C for 10 s (denaturation), at 58 -60°C (primer dependent) for 30 s, and 72°C for 5 s. All genes were normalized against the housekeeping gene GAPDH, which has been described as a stable reference gene for renal tissue in this experimental set-up (1, 39) . The details of each specific primer are provided in Table 1 .
NCC immunohistochemical staining. NCC staining was performed on formol-fixed, paraffin-embedded renal tissue using a rabbit antithiazide-sensitive NCC polyclonal antibody (Millipore, Brussels, Belgium). Before the immunohistochemical procedures, endogenous peroxidase activity in the rat kidney was blocked by H 2O2 (3% in H2O, 5 min). The tissue was trypsinized for 10 min at 37°C [50 mg trypsine in 50 ml buffer (10 mM Tris·HCl, pH 7.8, 0.1% NaCl, 0.1% CaCl 2·H2O)] and microwaved in a citrate buffer (0.3% citrate, pH 6, 2.47% Na citrate·5H2O) for 10 min, followed by preincubation with normal rabbit serum [1:5 in Tris-buffered saline (TBS: 10 mM Tris·HCl, pH 7.6, 0.9% NaCl, 0.1% Triton X-100, and 0.04% thimerosal)] for 20 min and overnight incubation with the primary antibody (1:100 in TBS). After washing in TBS, sections were treated with biotinylated goat anti-rabbit antiserum (1:200 in TBS), followed by the addition of the avidin-biotin peroxidase complex (Vector Laboratories, Burlingame, VT). Color development was performed with 3-amino-9-ethylcarbazole (AEC) as a chromogen in the presence of H 2O2. Just before being covered with a coverslip, sections were stained with hematoxylin and eosin.
AEC-stained sections were scanned with an Olympus BX61 Motorized Research Microscope equipped with analysis pro 5.0 software. After processing of the image, the total amount of AEC was measured and expressed as the percentage of the total cortex. The gray value of the AEC was also measured. A number from 0 to 155 was given to each slide, where 0 was black (chromogen) and 155 was white (background).
Statistics. Results are presented as means Ϯ SD. Differences between groups were investigated with one-way and two-way ANOVA followed by group-to-group comparisons with the post hoc Student-Newman-Keuls test. Nonparametric data were investigated with a Kruskal-Wallis test (tubular injury, claudin-19, claudin-16). Significant differences were assumed at the level of P Ͻ 0.05. Statistical analysis was computed using SPSS (version 18.0) for Windows.
RESULTS
Our rat model showed the expected functional and morphological characteristics of CsA nephrotoxicity as shown below.
Functional parameters. No rats died during the experiment. At the start of the study, there was no difference among the four groups in body weight or in laboratory values, i.e., serum creatinine, creatinine clearance, serum Mg 2ϩ , FE Mg 2ϩ , serum Na ϩ , and FE Na ϩ (data not shown). At the time of death, the mean body weight in both vehicle-treated groups was significantly higher than in the CsA-treated groups (P Ͻ 0.05) ( Table 2) . Serum creatinine values were significantly higher in the CsAtreated groups after 4 wk of treatment (P Ͻ 0.001). The serum Mg 2ϩ was significantly higher in the CsA-treated group with EGF vs. the controls (P ϭ 0.016). The FE Mg 2ϩ was significantly higher in the CsA-treated groups vs. the controls treated with EGF (P Ͻ 0.001). The serum Na ϩ was comparable in the four groups, but the FE Na ϩ was significantly increased in the CsA-treated groups vs. the control groups (P Ͻ 0.01). The potassium levels were slightly increased in the CsAtreated groups, although no significance was reached (P ϭ 0.136). The FE K ϩ was comparable in the four groups (P ϭ 0.297). The mean blood CsA level was 3,360.5 Ϯ 198.1 ng/ml in the CsA-treated group and 3,296.5 Ϯ 240.7 in the CsAϩEGF-treated group.
Serum aldosterone levels. Serum aldosterone levels were significantly lower in the CsA-treated rats (33.01 Ϯ 8.06 ng/ml) vs. controls (45.86 Ϯ 10.41 ng/ml, P ϭ 0.003).
CsA-induced morphological lesions. Three independent researchers agreed on the results. In the experimental groups, CsA caused mild tubular injury in the cortical areas. The mean score of tubular injury was 1.75 Ϯ 0.45 in CsA-treated rats (P ϭ 0.01 vs. controls) and 2.00 Ϯ 0.43 in CsA-treatedϩEGF rats (P Ͻ 0.0001 vs. controls and P ϭ 0.005 vs. controlϩEGF). In control rats, the mean score was 1.08 Ϯ 0.29 and in controlϩEGF rats the mean score was 1.25 Ϯ 0.45. CsA caused JGA hyperplasia (19 Ϯ 7%). There was no effect of EGF administration on the prevalence of JGA hyperplasia in CsA-treated rats (20 Ϯ 9%). In control rats, no JGA hyperplasia was observed. The four groups showed no difference in interstitial fibrosis: the mean score of interstitial fibrosis was 10.10 Ϯ 1.38% in CsA-treated rats and 11.21 Ϯ 1.80% in CsA-treatedϩEGF rats. In control rats, the mean score was 10.39 Ϯ 2.61%, and in controlϩEGF rats the mean score was 11.32 Ϯ 1.78%.
Phenotyping of inflammatory cells. In the control rats and the control rats treated with EGF, very few ED1-positive cells were detected in the total cortex area (Fig. 1 ). There was a significant infiltration of ED1-positive cells in the cortex of the rats treated with CsA (P ϭ 0.001). In the rats treated with CsA and EGF, a higher number of ED1-positive cells were detected than in control rats and rats treated with CsA alone, although this difference was not significant. There was no difference among the four groups regarding ED1-positive cells infiltrating the glomeruli (data not shown). The mean number of ED1-positive cells per glomerulus was 0.3 Ϯ 0.49.
Real-time RT-PCR.
The renal mRNA levels of TRPM6 (Fig. 2 ) were significantly downregulated in the CsA-treated rats [normalized ratio (NR) 1.25 Ϯ 0.32, P ϭ 0.029] and CsAϩEGF-treated rats (NR 0.99 Ϯ 0.13, P Ͻ 0.0001) vs. the controls (NR 1.48 Ϯ 0.24). TRPM6 was significantly upregulated in the controlsϩEGF rats (NR 1.77 Ϯ 0.25, P ϭ 0.005).
TRPM7 renal mRNA (Fig. 2) was significantly downregulated in both CsA-treated groups (NR CsA-treated rats: 1.35 Ϯ 0.40, P ϭ 0.035 and NR CsAϩEGF-treated rats: 0.99 Ϯ 0.23, P Ͻ 0.0001) vs. controls (NR 1.62 Ϯ 0.22).
The four groups showed no difference in renal mRNA expression of the EGFR (Fig. 2) . The renal mRNA expression of EGF (Fig. 2) significantly decreased in the CsA-treated groups (P Ͻ 0.0001) vs. both control groups. NR was 1.74 Ϯ 0.45 in the control group, 1.95 Ϯ 0.28 in the controlsϩEGF group, 0.51 Ϯ 0.39 in the CsA-treated group, and 0.49 Ϯ 0.14 in the CsAϩEGF-treated group. No significant differences have been found in the renal mRNA expression of claudin-16 (Fig. 3) between the CsAtreated group (NR 1.15 Ϯ 2.14) and the control rats (NR 0.97 Ϯ 2.37, P ϭ 1.000). Claudin-16 was significantly upregulated in the CsAϩEGF-treated group (NR 1.95 Ϯ 3.47, P ϭ 0.004) vs. control rats treated with EGF (NR 0.85 Ϯ 1.72). The four groups showed no difference in renal mRNA expression of claudin-19 (P ϭ 0.474, Fig. 3 ).
Renal mRNA of the NCC (Fig. 4) was significantly downregulated in the CsA-treated groups vs. both control groups (P Ͻ 0.01). NR was 0.91 Ϯ 0.24 in the control group, 0.91 Ϯ 0.26 in the controlsϩEGF group, 0.35 Ϯ 0.31 in the CsA-treated group, and 0.39 Ϯ 0.51 in the CsAϩEGF-treated group.
Renin mRNA expression (Fig. 4) was significantly upregulated in both CsA-treated groups (CsA: NR 1.14 Ϯ Renal mRNA levels of TGF-␤ were significantly increased in the CsA-treated rats (NR 1.61 Ϯ 0.36, P Ͻ 0.001) compared with the expression levels in the control rats (NR 1.11 Ϯ 0.16), control ratsϩEGF (NR 1.10 Ϯ 0.19), and CsAϩEGF-treated rats (NR 1.12 Ϯ 0.25). The mRNA levels of PAI-1 were the lowest in the control rats (NR 1.25 Ϯ 0.73). They were increased in the controlsϩEGF (NR 1.65 Ϯ 0.67) and the CsA-treated rats (NR 1.83 Ϯ 1.25), although not significantly. The mRNA of PAI-1 was significantly increased in the CsAϩEGF-treated rats (NR 2.20 Ϯ 0.19) vs. the controls (P ϭ 0.03), but not vs. both other groups.
NCC immunohistochemical staining. To assess whether the decreased mRNA levels corresponded with reduced protein expression, protein levels were semiquantified by immunohistochemistry. Table 3 shows that CsA significantly reduced the protein expression of the NCC. The NCC was significantly upregulated in the control rats treated with EGF. The intensity of the chromogen was significantly higher in the control rats vs. the three other groups.
DISCUSSION
In this study, we showed in vivo that CsA downregulates EGF, TRPM6 and TRPM7, and NCC, while both FE Mg 2ϩ and the FE Na ϩ increased. These results suggest that CsA treatment results in diminished renal Mg 2ϩ and Na ϩ reabsorption, respectively, via downregulation of the Mg 2ϩ channels TRPM6 and TRPM7 and the NCC. hEGF administration seemed to have a positive effect on Mg 2ϩ reabsorption in the control rats with an increase in TRPM6 renal mRNA and a decrease in FE Mg 2ϩ . This protective effect of hEGF administration was not maintained in CsA-treated rats.
The rat model of CsA nephrotoxicity was characterized by an increase in serum creatinine. FE Mg 2ϩ increased after 4 wk of treatment, conforming to what had been established in other studies (1, 28) . Our rat model showed the pathogenic characteristics of chronic CsA nephrotoxicity: the profibrotic factors PAI-1 and TGF-␤ were both upregulated as previously shown by our own research group and other investigators (10, 11, 48, 50) . The histological changes included tubular injury and JGA hyperplasia (47) . An additional upregulation of PAI-1 in the CsA group treated with EGF was found compared with the group treated with CsA alone. PAI-1 was also upregulated in the controls treated with EGF vs. the controls alone. We assume that this upregulation of PAI-1 was an effect of EGF administration. On the other hand, TGF-␤ was normalized in the CsA group treated with EGF compared with the group treated with CsA alone.
This study is the first to show in vivo downregulation of renal TRPM6 mRNA in CsA nephrotoxicity. In comparison, Nijenhuis et al. (33) found decreased renal mRNA levels of TRPM6 in tacrolimus-treated rats, another calcineurin inhibitor. We hypothesize that the mechanism leading to hypomagnesemia is similar in rats treated with tacrolimus and in rats treated with CsA and that CsA-induced hypomagnesemia is related to the decreased expression of the renal Mg 2ϩ channel TRPM6. This hypothesis is supported by the results of Ikari et al. (21) showing that CsA decreased TRPM6 expression and inhibited Mg 2ϩ influx in renal tubular epithelial NRK-52E cells. TRPM7 is very homologous to TRPM6 (Ϸ50% homology) and is also responsible for cellular Mg 2ϩ homeostasis (6, 31) . It was shown that TRPM6 specifically interacts with TRPM7 to form a functional ion channel complex at the cell surface of human embryonic kidney 293 cells (8, 25) . In our experiment, TRPM7 was downregulated in both experimental groups, even more in the EGF-treated CsA group. In contrast, Ikari et al. (21) did not find a CsA-induced downregulation of TRPM7 in vitro. However, since TRPM7 plays an important role in Mg 2ϩ homeostasis and since it forms functional complexes with TRPM6 in kidney cells, we hypothesize that this downregulation of TRPM7 could be important in CsA-induced renal Mg 2ϩ loss. It is not clear why this downregulation of TRPM7 was not detected in vitro. However, it remains unclear whether TRPM6 and TRPM7 are expressed on the DCT in rat kidneys, similar to the situation in mice and humans (38, 49) . In our hands, immunocytochemical stainings for both channels gave no results due to the unavailability of appropriate primary antibodies for the use in rats.
Simultaneous with the decrease in renal expression of TRPM6 and TRPM7, we found reduced expression of EGF in rats treated with CsA. This in vivo finding is in accordance with a mechanism which was previously revealed in vitro. EGF stimulates Mg 2ϩ reabsorption in the DCT via its receptor on the basolateral membrane and via activation of TRPM6 in the apical membrane in vitro (16, 41) . On the contrary, there was no difference in the expression of EGFR mRNA. This can be explained by the fact that the EGFR is expressed not only in the DCT but also in the proximal tubule (14, 23) . Since we have isolated total renal mRNA, we have also measured the EGFR in the proximal tubule. In this rat model, the effect of CsA seems to be predominantly directed against the DCT, with a downregulation of transporters which are only expressed in the DCT, namely, TRPM6 and the NCC, while mRNA expression of both claudin-16 and claudin-19 did not change, in contrast to what Chang et al. (7) found in cultured cortical TAL cells.
Until now, no relationship between TRPM7 and EGF has been described. We hypothesize that through the downregulation of EGF and TRPM6, TRPM7 is also affected in the DCT.
This study also addressed the CsA effect on NCC expression. FE Na ϩ was increased together with a downregulation of the NCC in rats treated with CsA. An increased FE Na ϩ after CsA treatment was found earlier in animal models without unraveling the underlying mechanisms (12, 26) . Also, in humans CsA causes hyponatremia or an increased FE Na ϩ after liver or renal transplantation (18, 51) . The downregulation of the NCC, the most important sodium transporter in the final adjustment of renal sodium excretion, could explain the increase in FE Na ϩ (15, 27) . This downregulation can be explained by the inactivation of the RAAS, which plays a role in NCC activation. ANG II is necessary to translocate the NCC to the plasma membrane, while both ANG II and aldosterone independently phosphorylate and thereby activate the NCC (37, 44). In our experiments, renal renin mRNA expression levels increased while serum aldosterone decreased in CsAtreated rats. Simultaneous with these findings, serum potassium levels slightly increased, as did FE Na ϩ while NCC expression decreased. Our results can be explained by an inhibition of the Values are means Ϯ SD and are presented for 4 groups: control animals receiving vehicle only, controlϩEGF, CsA, and CsAϩEGF. The gray value of 3-amino-9-ethylcarbazole (AEC) was measured, and a number from 0 to 155 was given to each slide, where 0 was black (chromogen) and 155 was white (background). Statistics were performed using 2-way ANOVA with a post hoc Student-Newman-Keuls test.
a P Ͻ 0.05 vs. conversion of inactive prorenin to active renin, resulting in an inactivation of the RAAS with low aldosterone secretion, which is comparable to data in humans (2, 30) . However, our study is the first to report a decrease in RAAS activity in rats treated with CsA whereas several groups have demonstrated that CsA is an activator of the RAAS in animals (24, 36) ; one study reports that CsA has no influence on renal renin mRNA expression (43) . This study also investigated the effect of EGF on Mg 2ϩ and Na ϩ homeostasis and DCT transporters after CsA treatment. In the control rats receiving hEGF, TRPM6 mRNA was significantly upregulated and FE Mg 2ϩ was decreased. These findings suggest that administration of hEGF has a positive effect on Mg 2ϩ homeostasis in control rats. In contrast, this positive effect was not maintained in CsA-treated rats. As expected, this beneficial phenomenon was not found for FE Na ϩ nor for the NCC and therefore was specific for Mg 2ϩ homeostasis. Claudin-16 significantly upregulated in CsAϩEGF-treated rats vs. controlsϩEGF. This unexpected data should be confirmed in other experiments to determine its significance. What factors could explain the differential effect of hEGF administration in controls and CsA-treated rats? First, a doserelated effect of EGF could be important. Possibly, the dose of EGF was too low in the CsA-treated rats to compensate for the downregulation of TRPM6, TRPM7, and EGF, while in the controls treated with EGF, the dose of hEGF was sufficient to reach the expected goal. Second, it is possible that due to kidney damage, the transporters could not be upregulated in the CsA-treated group. Hypothetically, a renoprotective treatment with L-arginine, resveratrol, or spirinolactone could diminish kidney damage after CsA treatment and restore the beneficial effect of EGF on Mg 2ϩ homeostasis in CsA-treated rats. Third, CsA may inhibit the signaling pathway activated by EGF. EGF activates various signaling pathways including ERK, P13K, and p38 MAP kinase. If CsA inhibits the signaling pathways, EGF administration can no longer exert its effect on TRPM6 expression in the CsA-treated rats. Further in vitro experiments are necessary to elucidate the mechanism by which CsA influences the EGF-TRPM6 signaling pathway.
Our finding that TRPM6 significantly increases in the controls treated with hEGF together with a decrease in FE Mg 2ϩ suggests that EGF administration could lead to an amelioration of Mg 2ϩ homeostasis through decreased renal Mg 2ϩ loss. In conclusion, the downregulation of TRPM6, TRPM7, and the NCC in combination with increased FE Mg 2ϩ and FE Na ϩ in our rat model suggest that the DCT transporters are important molecular players in CsA-induced nephrotoxicity. CsA administration had no effect on the expression of the paracellular proteins claudin-16 and claudin-19. This study indicates that CsA treatment undermines EGF expression and the RAAS, which results in decreased ion channel expression leading to hypomagnesemia and hyponatremia.
